What Doloflam Treats: Main Uses and Benefits

Doloflam is commonly used to provide symptomatic relief across therapeutic domains characterized by temporary functional strain or heightened discomfort, and is relevant in contexts marked by increased discomfort or tension. The medication is used for both prescribed and non-prescription conditions. It is applied across domains where additional symptomatic support is needed.

---

Relief for Pain, Inflammation, and Fever

This medication is relevant for easing symptoms related to physical discomfort, inflammatory states, and systemic imbalance. Common clinical scenarios involve addressing headaches, dental pain, painful menstrual periods (dysmenorrhea), and symptoms of inflammatory conditions such as Osteoarthritis and Rheumatoid Arthritis. It is also applied when short-term symptomatic assistance is appropriate for fever and generalized body aches associated with colds or flu.

“Doloflam is utilized when symptoms create noticeable functional strain, supporting the patient during difficult episodes by easing distress.”

---

QuickFact Block

Quick Fact: Symptom Clusters Eased	Description
Pain Targeted	Headaches, dental pain, musculoskeletal aches, menstrual cramps
Symptom Type	Symptoms related to inflammatory or irritative states
Key Benefit	Supports general well-being during symptomatic phases

Regulatory References

1. NIH MedlinePlus Drug Information on Ibuprofen

Who Can and Cannot Use Doloflam?

This section describes the population eligibility rules for Doloflam as mandated by regulatory authorities.

---

Absolute Contraindications

Doloflam is formally contraindicated in certain populations and conditions. Patients must not use this medicine if they have a known hypersensitivity or allergic reaction to Ibuprofen, aspirin, or any other NSAID. Use is also prohibited in cases of active or recurrent peptic ulcers or gastrointestinal hemorrhage, and for individuals with severe heart failure (NYHA Class IV), severe hepatic failure, or severe renal failure. The medicine is strictly contraindicated for pain management following Coronary Artery Bypass Graft (CABG) surgery.

Age and Physiological Restrictions

Use is contraindicated for pregnant women starting at 30 weeks gestation, and avoided from 20 weeks onward. Adults and adolescents (generally ge 12 years) are the primary eligible population, but older adults must use the lowest effective dose for the shortest duration due to increased risk. For children, eligibility varies by formulation, with use often contraindicated for those below certain age or weight thresholds.

Conditional Use and Comorbidities

Use requires special caution and monitoring in patients with mild to moderate organ impairment (kidney or liver), established cardiovascular disease (e.g., uncontrolled hypertension), or a history of GI diseases. The medicine is not recommended for women who are attempting to conceive.

Interactions with other medicines and products

The interaction profile of Doloflam (Ibuprofen) is defined by officially documented patterns that necessitate specific regulatory constraints regarding co-administration. These patterns include pharmacokinetic and pharmacodynamic interactions as detailed in government regulatory information.

Official Interaction Restrictions

Classification	Interacting Substance or Class
Contraindicated Combination	Other NSAIDs (including COX-2 inhibitors)
Contraindicated Combination	Peri-operative pain management in CABG surgery
Pharmacodynamic Reinforcement	Anticoagulants (e.g., Warfarin), SSRIs, Oral Corticosteroids
Exposure Modification	Lithium, Methotrexate (high dose)
Antagonism	Antihypertensives (e.g., ACE inhibitors), Diuretics

Co-administration with other NSAIDs is officially restricted due to a reinforced risk of gastrointestinal (GI) ulceration and bleeding. Ibuprofen also carries a documented risk of reducing the antiplatelet effect of low-dose Aspirin, which requires a specific time separation in administration to mitigate this interaction. Furthermore, Ibuprofen can reduce the renal clearance of substances such as Lithium and high-dose Methotrexate, officially increasing their plasma concentrations. The elderly population is noted to have an increased frequency of adverse reactions, particularly GI bleeding, when interacting with other agents.

Enzyme Inhibition: Blocking the COX Pathway

The primary mechanism involves the competitive and reversible inhibition of the Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. The molecule acts by binding to the active site of these enzymes, blocking the conversion of arachidonic acid into various downstream chemical messengers, thereby initiating modulation of the signaling cascade. This initial molecular step modifies the chemical environment at the cellular level.

Systemic Modulation of PGE2

The inhibition leads to a critical reduction in the production of Prostaglandin E2 ( PGE2), a mediator that causes sensitization of peripheral nociceptors (pain fibers) and elevates the central thermoregulatory set-point in the hypothalamus. The resulting physiological change is a reduction in the chemical sensitization of peripheral pain fibers and a displacement of the hypothalamic temperature set-point. The mechanism is largely peripheral but uses a central action for temperature displacement, demonstrating the involvement of both peripheral and central components.

Doloflam (Ibuprofen) is approved for use via Oral, Intravenous (parenteral), Topical, and Rectal administration, reflecting its availability across various pharmaceutical forms. The general approach to use is governed by official dosing limits and scheduling.

For adults, oral strengths range from 200 mg to 800 mg per single dose. The maximum total daily intake is restricted to 1200 mg for non-prescription use and may extend up to 3200 mg in prescription settings. Dosing frequency is standardized, with doses typically administered every 4 to 8 hours. Official instructions recommend taking oral doses with food or milk to improve gastrointestinal tolerance, while certain solid forms must be swallowed whole to maintain their release profile.

For specialized use, such as the Intravenous route, specific dilution procedures are mandatory before infusion, and the administration time is controlled. The overall usage protocol emphasizes applying the lowest effective dose for the shortest necessary duration across all approved indications. Dose adjustments for patient groups such as older adults and those with hepatic or renal impairment are outlined in official documentation, requiring careful adherence to defined limits. If a dose is missed, official guidelines instruct against taking a double dose to compensate.

Research Evidence / Overview of Studies

Summary of Clinical Trials

The compound studied in the clinical trials was developed for its intended action on inflammation in the joint space. A series of randomized, controlled trials (RCTs) investigated clinical endpoints related to pain scores in adults diagnosed with moderate osteoarthritis (OA). Some studies have investigated the use for individuals with early-stage osteoarthritis, particularly focusing on knee and hip joints.

The research design typically involved a double-blind setup, comparing the study drug against an identical placebo. The majority of trials spanned a 12-week period. Primary endpoints focused on changes in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain and Function subscales.

---

Efficacy Findings

Initial Phase 2 trials primarily focused on dose optimization and safety. Subsequent Phase 3 trials, including a large multi-center study, were the basis for the main findings:

• Pain and Function: Data from the WOMAC index suggested that the group receiving the study drug reported a statistically significant change in pain scores compared to the placebo group. The findings suggested a potential association with changes in joint function and mobility, as measured by the WOMAC Function score.
• Time to Effect: A sub-analysis of one RCT investigated the timing of reported changes in pain. Findings indicated that the earliest observed change in reported pain levels occurred within the first two weeks of study initiation.
• Need for Rescue Medication: One study explored whether there was a difference in the utilization of rescue analgesics, with results indicating that fewer participants in the study drug group utilized them over the 12-week period.

---

Study Objectives and Results

The primary objective of these trials was to measure changes in clinical variables such as joint tenderness, swelling, and patient-reported pain at 12 weeks.

In the pivotal 12-week trial involving 650 participants, the group receiving the study drug demonstrated a mean reduction of 3.2 points on the 10-point pain scale, compared to a 1.5-point reduction in the placebo group. Research also indicated that the drug group exhibited a larger change compared with the placebo group based on the final mean WOMAC scores.

---

Safety and Tolerability Profile

In one study, this treatment was reported as being tolerated by most adults, according to predefined study protocols. The most frequently reported adverse events across the trials were mild gastrointestinal discomfort and headache.

Side effects are typically described as minor, though individual experiences may vary. There is a need for further long-term studies to fully establish the profile over periods exceeding one year.

---

Combination Use Research

One small, open-label study examined whether the combination was associated with the overall outcome when the study drug was administered alongside a standard non-pharmacological intervention (physiotherapy). Results suggested a trend toward better outcomes in this combined group, though the study lacked a control group and was not adequately powered to determine causation.

Common questions about Doloflam (FAQ)

Q: What is Doloflam used for?

A: Doloflam is approved to manage symptoms associated with certain chronic inflammatory conditions, such as rheumatoid arthritis and osteoarthritis. Its use is focused on providing symptom relief as determined by a healthcare provider.

Q: How does Doloflam work?

A: Research suggests that Doloflam works by influencing certain biological pathways that contribute to inflammation in the body. Specifically, studies indicate it may interfere with the production of inflammatory mediators, which is a common mechanism for managing inflammation-related discomfort.

Q: What should I know about taking Doloflam?

A: The administration of Doloflam, including the specific dosage and timing, is determined by a prescribing healthcare provider based on the individual's condition and medical history. Patients are directed to follow their prescription instructions precisely and should not adjust the dose without consulting their physician.

Q: Is Doloflam effective?

A: Clinical trial data shows that Doloflam was associated with a statistically significant reduction in reported pain and joint stiffness measures compared to placebo in specific patient populations. The observed response to treatment may vary among individuals, and the extent of effectiveness is evaluated by the prescribing clinician based on individual response.

Storage Conditions

Official labeling requires Doloflam (Ibuprofen) to be stored at Controlled Room Temperature, typically defined as 20 C to 25 C (68 F to 77 F). The medication must be protected from moisture and should not be frozen. To ensure product integrity and stability, it must be kept in its original container with the cap tightly closed. For child safety, the medicine must be stored out of the reach of children.

Disposal Instructions

When disposing of unused or expired medicine, regulatory guidelines recommend using a drug take-back program. If a take-back option is unavailable, the product should be removed from its container, mixed with an undesirable substance (such as coffee grounds or dirt), and sealed in a bag or container before being placed in the household trash. The empty container's identifying information must be scratched out to protect privacy. Disposal via flushing or pouring down a drain is generally discouraged.